Vectura Vectura News Discover more about our company, science, innovation and people with the latest headlines from Vectura. Displaying 12 of 64 Vectura wins Mediscience’s Best Communication Award Published17/11/2021 READ MORE Our CDMO expertise in the spotlight Published24/08/2021 READ MORE Vectura at CPhI North America 2021: July 26 – August 6 Published26/07/2021 READ MORE Vectura Signs Pre-Clinical Development Agreement with Incannex to Advance IHL-216A for the Treatment of Traumatic Brain Injury Published22/06/2021 READ MORE Shortlisted for Best Sustainability Reporting: Healthcare Published15/06/2021 READ MORE Vectura announces completion of management buy-out of Lyon oral subsidiary, Skyepharma Production SAS Published10/06/2021 READ MORE Vectura at BIO Digital, June 10-11 & 14-18, 2021 Published09/06/2021 READ MORE Vectura and Inspira Pharmaceuticals Sign Agreement to Develop Potential Inhaled Treatment for COVID-19 Published06/05/2021 READ MORE Showcasing our scientific expertise at Respiratory Drug Delivery Congress (RDD) 4th-7th May, 2021 Published28/04/2021 READ MORE Vectura highlights update made by Hikma on launch of generic Advair Diskus® Published21/04/2021 READ MORE “Strategies for rapid progression of inhaled products” at Formulation & Delivery Europe Congress: Online Published15/04/2021 READ MORE Will Downie named in The Medicine Maker’s Power List for 2021 Published15/04/2021 READ MORE 1 2 3 … 6 next » Displaying 12 of 64 CAREERS ACCESSIBILITY TERMS & CONDITIONS COMMITMENT TO INCLUSIVITY MODERN SLAVERY ACT GENDER PAY GAP PRIVACY POLICY COOKIE STATEMENT SITE MAP BREELIB™ INSTRUCTIONS FOR USE ©2021 Vectura Group plc Designed and Developed by Naked Ideas

Vectura About Vectura Inhalation is our focus. With more than 20 years’ experience, we can help you succeed in bringing inhaled medicines to market. Track Record Our partners have succeeded in bringing DPI, pMDI and nebuliser medicines to market with the help of our specialist capabilities. Our combination of formulation science, device technology and inhaled development expertise has contributed to the success of 13 inhaled medicines, launched by our partners and licensees. Since launch, they have generated $11 billion in sales and in 2020 these products were used by 10 million patients worldwide. MORE INFORMATION 20+ years' experience in inhaled product development 13 inhaled on-market medicines, launched by our partners and licensees $11bn total sales of products using our formulation and device technology since launch 10m patients using products utilising Vectura’s intellectual property in 2020 CAREERS ACCESSIBILITY TERMS & CONDITIONS COMMITMENT TO INCLUSIVITY MODERN SLAVERY ACT GENDER PAY GAP PRIVACY POLICY COOKIE STATEMENT SITE MAP BREELIB™ INSTRUCTIONS FOR USE ©2021 Vectura Group plc Designed and Developed by Naked Ideas